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Efficacy and Safety of Trabeculectomy
vs Nonpenetrating Surgical Procedures
A Systematic Review andMeta-analysis
Eliana Rulli, ScD; Elena Biagioli, ScD; Ivano Riva, MD; Giovanni Gambirasio, MD; Irene De Simone, ScD;
Irene Floriani, PhD; Luciano Quaranta, MD
IMPORTANCE To date, only a few studies have directly compared nonpenetrating surgery
(NPS) and trabeculectomy (TE). Therefore, there is no strong evidence as to which surgical
technique leads to the best results in terms of ocular hypotensive effect and safety.
OBJECTIVE To compare the hypotensive effect and safety of NPS and TE in terms of
intraocular pressure (IOP) reduction and incidence of complications.
DATA SOURCES TheMEDLINE and EMBASE databases were searched for studies potentially
eligible in any language published up toMarch 31, 2013.
STUDY SELECTION Systematic review andmeta-analysis of comparative studies of 2 or more
surgical techniques (1 of which had to be TE), including patients with open-angle glaucoma.
DATA EXTRACTION AND SYNTHESIS The considered interventions were TE, deep sclerectomy
(DS), viscocanalostomy, and canaloplasty.
MAIN OUTCOMES ANDMEASURES The primary outcomewas themean between-group
difference in the reduction in diurnal IOP from baseline to the 6- or 12-month follow-up
evaluation. We also considered the incidence of complications, expressed as relative risk.
RESULTS Eighteen articles, accounting for 20 comparisons, were selected for data extraction
and analysis. Analysis of the 6-month follow-up data showed that the pooled estimate of the
mean between-group difference was −2.15 mmHg (95% CI, −2.85 to −1.44) in favor of TE.
There was no difference between the NPS subgroups. In the subgroup antimetabolite
analysis, the addition of mitomycin C to TE and DS decreased the difference in the reduction
in IOP (TE and DS without mitomycin C: −2.65mmHg [95% CI, −3.90 to −1.39]; TE and DS
with mitomycin C: −0.83mmHg [95% CI, −2.40 to 0.74]). In the subgroup analysis by
implant addition, no significant difference induced by DS with or without drainage devices
was detected (test for subgroup differences: χ21 = 0.24; P = .62). The absolute risk of
hypotony, choroidal effusion, cataract, and flat or shallow anterior chamber was higher in the
TE group than in the NPS group.
CONCLUSIONS AND RELEVANCE Trabeculectomy seems to be themost effective surgical
procedure for reducing IOP in patients with open-angle glaucoma. However, as expected, it
was associated with a higher incidence of complications when compared with NPS.
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T rabeculectomy (TE) involves draining aqueous humorfrom the anterior chamber into the subconjunctivalspaces through a sclerostomy and requires full-
thicknesspenetrationof the anterior chamberunder apartial-
thickness scleral flap.1 It is considered to be the standard pro-
cedure for lowering intraocular pressure (IOP) inpatientswith
glaucoma,1-3 but it is frequently accompanied by short- and
long-termcomplications suchashypotony,4,5 bleb leaks,6-9 ac-
celerated cataract progression,10 choroidal effusion and
hemorrhaging,11 and prolonged or permanent visual impair-
ment due to hypotonymaculopathy.4,12 These complications
are generally increased by the use of antifibrotics (also called
antimetabolites) suchas5-fluorouracil ormitomycinC (MMC),
but without them, the incidence of short-term failure is rela-
tively high.13,14
Therehas recently been renewed interest innonpenetrat-
ing surgery (NPS) for glaucoma, which was developed to im-
prove the safety of conventional filtering procedures. The 3
main variations of NPS are deep sclerectomy (DS),15-18 visco-
canalostomy (VCO),19 and canaloplasty (CP).20,21 Deep scle-
rectomy is a filtering procedure for which success often re-
quires bleb formation, which is infrequent in the case of VCO
andCP as the reduction in IOP ismainly due to the opening of
previously nonfunctional areas of the Schlemmcanal. Antifi-
brotics are frequently used in DS but never in VCO and CP.
Moreover, it hasbeen suggested that theuseof collagendrain-
age devices positioned under the scleral flap would improve
aqueous humor filtration.22-24
As only a fewstudies havedirectly comparedNPS andTE,
there isnostrongevidenceas towhichsurgical technique leads
to the best results in terms of hypotensive effects and safety.
The aimof this systematic reviewandmeta-analysis of aggre-
gate data is to fill this gap.
Methods
To avoid the bias induced by post hoc decisions, the eligibil-
ity criteria andmethods of analysiswere specified in advance
anddocumented in a protocol described here. As this is a sys-
tematic review analyzing data already published, we did not
enroll patientsand institutional reviewboardapprovalwasnot
required.
Eligibility Criteria
Weselectedexperimental andobservational comparativestud-
ies of 2 ormore surgical techniques (1 of which had to be TE).
Patients
Thestudies involvedpatientswithopen-angleglaucoma(OAG),
regardless of age, race/ethnicity, or sex. Open-angle glau-
comawasdefined as the following: (1) anuntreatedmean IOP
greater than 21 mm Hg; (2) open drainage angles detected by
gonioscopy; (3) typical optic disc damagewith glaucomatous
cupping and loss of the neuroretinal rim; and (4) visual field
defects compatible with glaucomatous optic neuropathy.25
Studies includingpatientswith exfoliative glaucoma (XFG) or
pigment dispersion syndrome were considered eligible,
whereas those including patients with neovascular glau-
coma, secondaryglaucoma,ornormal-tensionglaucomawere
excluded.Mixed study populations of patients with OAG and
patients with chronic angle-closure glaucoma were also con-
sidered eligible.
Interventions
The considered interventions were TE, DS, VCO, and CP, in-
cluding TE and DS with intraoperative antimetabolite aug-
mentation and DS with a scleral implant. Studies including
combined cataract and glaucoma surgerywere excluded, un-
less thedata relating toglaucomasurgeryweredescribedsepa-
rately.
OutcomeMeasures
The primary outcome was the mean between-group differ-
ence (MeD) in the reduction indiurnal IOP frombaseline to the
6-or 12-monthfollow-upevaluation.Unfortunately,even ifpro-
gression of visual field damage is the main outcome of glau-
coma treatments, there is a lack of literature on comparison of
surgical techniques (TEvsNPS) andprogressionofvisual field.
Thus, itwasnotpossibletoperformsuchsystematicreviewwith
thisoutcome.Sixmonthswasconsidered tobe theminimal fol-
low-up period to ensure IOP stabilization after surgery; there-
fore, studies with a shorter follow-up were excluded. We also
considered the incidence of complications, expressed as rela-
tive risk (RR). Significant complications (including hypotony,
choroidal effusion, cataract, and flat or shallowanterior cham-
ber) were prespecified in the data extraction form.
Search Strategies
TheMEDLINEandEMBASEdatabaseswere searched for stud-
ies in any language published up to March 31, 2013 (eTable 1
in Supplement). However, non-English-language articles for
whichno full-text translationor evaluationwasavailablewere
excludedduring thescreeningphase.The reference listsof trial
reports aswell as narrative and systematic reviewswerehand
Figure 1. Study Selection
210 Records identified through
PubMed search
278 Records screened after
duplicates removed
40 Full-text articles assessed
for eligibility
18 Studies included in analysis
238 Records excluded
128 Records identified through
EMBASE search
22 Full-text articles excluded
6 Other types of surgery
3 Closed-angle or secondary
glaucoma
1 Other end point
8 Not clinical study
3 Chinese or Romanian
language
1 Short follow-up
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searched to identify additional studies.Three reviewers (abio-
statistician [I.F.] and 2 ophthalmologists [L.Q. and I.R.]) inde-
pendently checked the titles, abstracts, and keywords of the
identified studies to ensure eligibility and then read the full
articles to identify those that met the inclusion criteria; any
disagreements were resolved by consensus. A κ statistic was
calculated formeasuring agreementbetween the reviewers.26
Data Extraction
The study design, patient characteristics, interventions, and
outcomeswere independently recordedby 2 reviewers (I.D.S.
andG.G.)usingadataextraction formthathadbeenpilot tested
on4 randomly selected studies andsubsequently refined.Any
differences in data extraction were resolved by a third re-
viewer (I.R.), who referred back to the original article.
Risk of Bias Assessment
The quality of the studies was independently evaluated by 2
reviewers (E.R. and E.B.) using the approach proposed by the
CochraneCollaboration for theexperimental studies27 and the
Newcastle-Ottawa Scale for the observational studies.28
Statistical Analysis
Thereduction in IOP ineacheligiblearmof the individual stud-
ieswascalculatedas thedifferencebetween thevaluesatbase-
line and the different follow-up times, and its variance was
computed as the weightedmean of their variances. TheMeD
was thencomputedas thebetween-treatmentdifference in the
IOP reduction from baseline.
For studies with more than 2 eligible groups to be in-
cluded in the samemeta-analysis, the control groupwas split
into 2 ormore groupswith smaller sample size to overcome a
unit of analysis error.27
To evaluate the assumptions in the variance computa-
tion, the ρ correlation coefficient for paireddata (baseline and
follow-up IOP) was calculated and assessed using the ap-
proach suggested by the Cochrane Collaboration.27
The absolute value of theMeD indicates the size of the ef-
fect difference,whereas the sign indicates thedirectionof this
effect. A value of 0 suggests no difference in efficacy be-
tween thegroups.PooledMeDestimateswerecalculatedusing
the 2-stepmethod for the random-effectsmodel proposed by
DerSimonian and Kacker.29
Table 1. Description of Studies and Patients
Source Design Masking
Withdrawals
and
Dropouts
Described Diagnosis
Patients
Enrolled/
Analyzed,
No.
Eyes
Enrolled/
Analyzed,
No.
Male,
%
Age, Mean
(SD), y
White,
%
Ayyala et al,33 2011 Observational Open label Yes POAG 79/79 79/79 54 66.1 (11.0) 46
Gilmour et al,40 2009 Experimental
(randomized)
Not reported No POAG + XFG 43/U 50/42 67 64.4 (10.3) 100
Russo et al,45 2008 Experimental
(randomized)
Not reported Yes POAG 93/93 93/93 51 67.3 (2.7) U
Yarangümeli et al,48
2004
Experimental
(randomized)
Not reported Yes POAG + XFG + CACG 22/22 44/44 45 64.3 (10.5) U
Cillino et al,36 2004 Experimental
(randomized)
Outcome assessor
masked
Yes POAG + XFG 35/35 35/35 49 70.0 (1.5) U
Yalvac et al,47 2004 Experimental
(randomized)
Not reported U POAG 50/50 50/50 72 60.2 (11.5) U
Schwenn et al,46 2004 Experimental
(randomized)
Open label Yes POAG 22/22 22/22 50 68.3 (11.7) U
Egrilmez et al,38 2004 Experimental
(randomized)
Not reported Yes POAG + XFG + PDS 34/30 34/30 57 61.7 (10.9) 100
Carassa et al,34 2003 Experimental
(randomized)
Outcome assessor
masked
Yes POAG + XFG 50/49 50/49 40 67.7 (13.4) 100
Kobayashi et al,42 2003 Experimental
(randomized)
Not reported U POAG 25/25 50/50 44 62.5 (7.4) 100
Lüke et al,43 2002 Experimental
(randomized)
Not reported U POAG + XFG + PDS 60/60 60/60 48 61.4 (17.6) 95
Ambresin et al,32 2002 Experimental
(nonrandomized)
Not reported U POAG + XFG + PDS 20/20 40/40 50 68.0 (12.6) 95
Chiselita,35 2001 Experimental
(randomized)
Outcome assessor
masked
U POAG 17/17 34/34 53 60.17 (7.3) U
El Sayyad et al,39 2000 Experimental
(randomized)
Not reported U POAG 39/39 78/78 63 53.4 (9.6) U
Mermoud et al,44 1999 Observational Not reported Yes POAG + XFG 93/88 93/88 51 68.8 (13.0) 99
Cillino et al,37 2008 Experimental
(randomized)
Not reported U POAG + XFG 40/40 40/40 50 70.3 (6.7) U
Jonescu-Cuypers et al,41
2001
Experimental
(randomized)
Not reported U POAG 20/20 20/20 55 62.5 (13.1) 100
Mesci et al,49 2012 Experimental
(randomized)
Outcome assessor
masked
Yes POAG + XFG 99/91 99/91 48 68.0 (10.2) U
Abbreviations: CACG, chronic angle-closure glaucoma; PDS, pigment dispersion syndrome; POAG, primary open-angle glaucoma; U, unknown;
XFG, exfoliative glaucoma.
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Safety was assessed in terms of the incidence of intraop-
erativeandpostoperativecomplications ineachgroup.Thedif-
ference between groups was expressed as the RR.
All results were expressed as a point estimate and its 95%
confidence interval.
Statistical heterogeneity was quantified using the I2 sta-
tistic, which indicates the percentage of variability due to
heterogeneity rather than to chance alone: 0% indicates no
heterogeneity, greater values indicate increasing heteroge-
neity, and values greater than 50% imply substantial
heterogeneity.30
Wealso used χ2 tests for homogeneity. The assumptionof
homogeneity was deemed not valid if P < .10.
All of the statistical analyses were performed using Re-
view Manager version 5.1 software (Nordic Cochrane Centre,
Cochrane Collaboration).
Efficacy Analysis
The primary analysis compared TE and NPS after 6 and 12
months of follow-up in terms of theMeD. In the case of stud-
ieswithno6- or 12-month assessment,we considered the IOP
recorded at the nearest subsequent evaluation. Subgroup
analyses were made by type of NPS (DS, VCO, and CP), anti-
metaboliteaugmentationduringsurgery (only for studiescom-
paring TE and DS), and the use of implants (only for studies
comparing TE andDS). To verify the robustness of the results
of theprimary analysis, the analyseswere repeatedbyexclud-
ing the studies not assessing IOP at 6 or 12 months and by ex-
cluding nonrandomized studies.
Safety Analysis
The safety analysis compared TE with one of the NPS proce-
dures in terms of the incidence of complications. Each com-
plication was analyzed separately.
Publication Bias Assessment
To exclude the presence of publication bias (ie, the bias due
to the fact that studieswith positive results aremore likely to
be published than those with negative results) and small-
study effects (the tendency for treatment effect estimates to
be different in small and larger studies), we visually explored
anyasymmetryusinga funnelplot inwhichstudysizewasplot-
ted as a function of the measure of interest.31
Results
Figure 1 shows the study selection process. The electronic
searches identified 278 abstracts, 238 of which did not meet
the eligibility criteria; the full texts of the remaining 40 ar-
ticles were examined. No additional studies were identified
from the references of the selected articles, and no relevant
Table 2. Surgery Characteristics
Source TE NPS
Postoperative
Treatment Goniopuncture Implant
Ayyala et al,33 2011 With MMC (0.4 mg/
mL × 45 s)
CP MMC (TE only) No No
Gilmour et al,40
2009
No antimetabolite VCO 5-FU Yes No
Russo et al,45 2008 With MMC (0.2 mg/
mL × 2 min)
DS + MMC (0.2 mg/
mL × 2 min)
5-FU No SK-Gel
Yarangümeli et al,48
2004
No antimetabolite VCO None Yes No
Cillino et al,36 2004 No antimetabolite DS (no antimetabolite) None No No
Yalvac et al,47 2004 No antimetabolite VCO None No No
Schwenn et al,46
2004
With MMC (0.2 mg/
mL × 5 min)
DS + MMC (0.2 mg/
mL × 5 min)
5-FU No SK-Gel
Egrilmez et al,38
2004
No antimetabolite DS (no antimetabolite),
VCO
None No T-Flux
Carassa et al,34
2003
No antimetabolite VCO 5-FU Yes No
Kobayashi et al,42
2003
With MMC (0.4 mg/
mL × 3 min)
VCO None Yes No
Lüke et al,43 2002 No antimetabolite VCO None No No
Ambresin et al,32
2002
No antimetabolite DS (no antimetabolite) 5-FU Yes SK-Gel
Chiselita,35 2001 No antimetabolite DS (no antimetabolite) None No no
El Sayyad et al,39
2000
No antimetabolite DS (no antimetabolite) 5-FU Yes no
Mermoud et al,44
1999
No antimetabolite DS (no antimetabolite) 5-FU Yes SK-Gel
Cillino et al,37 2008 With MMC (0.2 mg/
mL × 2 min)
DS + MMC (0.2 mg/
mL × 2 min)
None Yes No
Jonescu-Cuypers
et al,41 2001
No antimetabolite VCO None No No
Mesci et al,49 2012 No antimetabolite DS + MMC (0.2 mg/
L × 2 min)
MMC Yes SK-Gel,
no
Abbreviations: CP, canaloplasty;
DS, deep sclerectomy; MMC,
mitomycin C; NPS, nonpenetrating
surgery; TE, trabeculectomy;
VCO, viscocanalostomy;
5-FU, 5-fluorouracil.
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unpublishedstudieswere found.A further22studiesweresub-
sequently excluded (eTable 2 in Supplement): 6 because they
investigated other types of surgery, 3 because they included
patientswith secondary glaucoma or closed-angle glaucoma,
1 because it had adifferent endpoint, 8 because theywerenot
clinical studies, 1 because the follow-up was too short, and 3
because theywerenotwritten inEnglishandno full-text trans-
lation or evaluationwas available. For the abstract screening,
the agreementwas good (κ = 0.70); regarding the full-text ar-
ticle screening, we obtained full agreement between the re-
viewers.
Eighteenarticleswere thereforeselectedfordataextraction
andanalysis,32-49 but as 2of themprovided2comparisons,38,49
the total number of comparisonswas 20.
Study Characteristics
Table 1 shows the characteristics of the 18 studies. Fifteen
were randomized clinical trials,34-43,45-49 1 was a nonran-
domized experimental study,32 and 2 were observational
studies.33,44
Information about the blindness assessment was not
clearlydescribed in 12 articles.32,37-45,47,48Onearticle40didnot
describewithdrawalsordropouts, and8articles32,35,37,39,41-43,47
did not clearly indicate the presence of withdrawals or drop-
outs. Eight studies33,35,39,41,42,45-47 only includedpatientswith
primary OAG (POAG), 6 studies34,36,37,40,44,49 included pa-
tients with POAG and XFG, 3 studies32,38,43 included patients
with POAG, XFG, and pigment dispersion syndrome, and 1
study48 includedpatientswithPOAG,XFG, andchronic angle-
Figure 2. Trabeculectomy vs Nonpenetrating Surgery at 6-Month Follow-up
–15 0 10 15–5 5
Favors TE Favors NPS
–10
Source
TE vs VCO
TE vs DS
Mean Difference, IV,
Random (95% CI)
Mean Difference, IV,
Random (95% CI)
Carassa et al,34 2003 –1.83 (–6.34 to 2.68)
Egrilmez et al,38 2004 –5.92 (–18.37 to 6.53)
Gilmour et al,40 2009 –2.58 (–6.15 to 0.99)
Jonescu-Cuypers et al,41 2001 0.40 (–6.32 to 7.12)
Kobayashi et al,42 2003 –4.90 (–7.39 to –2.41)
Lüke et al,43 2002 0.80 (–3.26 to 4.86)
Yalvac et al,47 2004 –3.80 (–9.35 to 1.75)
Yarangümeli et al,48 2004 –2.60 (–10.22 to 5.02)
Subtotal  –2.84 (–4.40 to –1.27)
Heterogeneity: τ 2 = 0.14, χ 2 = 7.18 (P =.41), I 2 = 3%
Test for overall effect: Z = 3.55 (P <.001)
Egrilmez et al,38 2004 –3.13 (–13.32 to 7.06)
Mermoud et al,44 1999 –1.70 (–5.15 to 1.75)
Mesci et al,49 2012 –2.00 (–3.94 to –0.06)
Mesci et al,49 2012 –1.70 (–3.80 to 0.40)
Cillino et al,36 2004 –3.00 (–5.06 to –0.94)
Cillino et al,37 2008 1.00 (–3.23 to 5.23)
Russo et al,45 2008 –1.00 (–2.71 to 0.71)
El Sayyad et al,39 2000 –1.50 (–4.71 to 1.71)
Schwenn et al,46 2004 –6.50 (–17.87 to 4.87)
Subtotal  –1.91 (–2.72 to –1.10)
Heterogeneity: τ 2 = 0.00, χ 2 = 8.72 (P =.56), I 2 = 0%10
Test for overall effect: Z = 4.64 (P <.001)
TE vs CP
Ayyala et al,33 2011 –3.10 (–7.63 to 1.43)
Subtotal –3.10 (–7.63 to 1.43)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P =.18)
Mean
Difference
–1.83
–5.92
–2.58
0.40
–4.90
0.80
–3.80
–2.60
–3.13
–1.70
–2.00
–1.70
–1.00
–1.50
–6.50
–3.00
1.00
–3.10
–7.50
–2.35
SE
2.30
6.35
1.82
3.43
1.27
2.07
2.83
3.89
5.20
1.76
0.99
1.07
0.87
1.64
5.80
1.05
2.16
2.31
2.87
1.22
Weight, %
2.4
0.3
3.9
1.1
8.0
3.0
1.6
0.9
21.3
0.5
4.2
13.2
11.3
17.1
4.8
0.4
76.3
Total –2.15 (–2.85 to –1.44)
Heterogeneity: τ 2 = 0.00, χ  2 = 17.27 (P =.57), I 2 = 0%
Test for overall effect: Z = 5.96 (P <.001)
2
19
Test for subgroup differences: χ 2 = 1.38 (P =.50), I 2 = 0%
100.0
11.7
2.8
2.4
2.4
1.6
8.7
Ambresin et al,32 2002 –7.50 (–13.13 to –1.87)
Chiselita,35 2001 –2.35 (–4.74 to 0.04)
7
CP indicates canaloplasty; DS, deep sclerectomy; IV, inverse-variancemethod; NPS, nonpenetrating surgery; TE, trabeculectomy; and VCO, viscocanalostomy.
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closureglaucoma.Thereweremorementhanwomenin9stud-
ies, and the patients’ ages ranged from 53.4 to 70.3 years.
Risk of Bias
Selectionbias couldnot beexcluded in 15of the 16 experimen-
tal studies because of the absence of adequate sequence gen-
eration or concealed allocation (3 studies)32,36,45 or lack of in-
formation (12 studies).34,35,37-41,43,46-49 Attrition bias could be
excluded in 6 experimental studies34,38,45,46,48,49 that ad-
dressed thequestionof incomplete outcomedata; the rates of
follow-up and the number of withdrawals were similar be-
tween thegroups.Only4of the 16 experimental studies34-36,49
stated that the outcome assessors were unaware of the as-
signed intervention.
The 2 observational studies33,44 had a low risk of bias, but
theobservational design limitations shouldbe taken into con-
sideration.
Effects of Interventions
The18studiesmadea totalof 20comparisonsand involved945
eyes: 7 studies34,40-43,47,48 compared TEwith VCO (315 eyes); 1
study33 compared TEwith CP (79 eyes); 8 studies32,35-37,39,44-46
compared TE with DS (430 eyes); 1 study38 compared TE with
DSandVCO (30eyes); and 1 study49 comparedTEwithDSwith
or without an implant (91 eyes). Mitomycin Cwas the only an-
timetabolite added at the time of surgery in 7 comparisons of
TE and DS (Table 2).
TE vs NPS
Analysisof the6-month follow-updata showedthat thepooled
estimate of theMeDwas −2.15mmHg (95%CI, −2.85 to −1.44;
test for overall effect:Z = 5.96,P < .001); noheterogeneitywas
detected (I2 = 0%; test for heterogeneity: χ219 = 17.27, P = .57)
(Figure 2).
There was no difference between the surgical subgroups
indicating that TE led to a greater IOP reduction.
In the subgroup antimetabolite analysis (Figure 3), 6
studies32,35,36,38,39,44 compared TE and DS without MMC
(MeD = −2.65mmHg [95%CI, −3.90 to−1.39]), 3 studies37,45,46
comparedTEandDSwithMMC(MeD = −0.83mmHg [95%CI,
−2.40 to0.74]), and 1 study49 comparedTEwithoutMMCwith
DSwithMMC (MeD = −1.86mmHg [95%CI, −3.29 to −0.44]).
In the subgroup analysis of the studies in which an im-
plantwasadded toDS, therewere5 studies35-37,39,49ofDSwith-
Figure 3. Subgroup Analysis of Antimetabolite Addition for Trabeculectomy vs Deep Sclerectomy at 6-Month Follow-up
–15 0 10 15–5 5
Favors TE Favors DS
–10
Source
TE (no MMC) vs DS (no MMC)
Mean Difference, IV,
Random (95% CI)
Mean Difference, IV,
Random (95% CI)
Ambresin et al,32 2002 –7.50 (–13.13 to 1.87)
Chiselita,35 2001 –2.35 (–4.74 to 0.04)
Cillino et al,36 2004 –3.00 (–5.06 to –0.94)
Egrilmez et al,38 2004 –3.13 (–13.32 to 7.06)
Mermoud et al,44 1999 –1.70 (–5.15 to 1.75)
El Sayyad et al,39 2000 –1.50 (–4.71 to 1.71)
Subtotal  –2.65 (–3.90 to –1.39)
Heterogeneity: τ2 = 0.00, χ 2 = 3.82 (P =.58), I 2 = 0%
Test for overall effect: Z = 4.13 (P <.001)
5
TE (+MMC) vs DS (+MMC)
Cillino et al,37 2008 1.00 (–3.23 to 5.23)
Subtotal
Heterogeneity: τ2 = 0.00, χ 2 = 1.71 (P =.42), I 2 = 0%
Test for overall effect: Z = 1.04 (P =.30)
Mean
Difference
–7.50
–2.35
–3.00
–3.13
–1.70
–1.50
1.0
SE
2.87
1.22
1.05
5.20
1.76
1.64
2.16
Weight, %
2.1
11.4
15.4
0.6
5.5
6.3
41.3
2
1
10
3.6
–1.00 (–2.71 to 0.71)–1.0 0.87 22.4
–6.50 (–17.87 to 4.87)–6.5 5.80 0.5
–0.83 (–2.40 to 0.74)26.6
–1.91 (–2.72 to –1.10)100.0
Russo et al,45 2008
Schwenn et al,46 2004
 –1.86 (–3.29 to –0.44)32.1
–1.70 (–3.80 to 0.40)–1.7 1.07 14.8
TE (no MMC) vs DS (+MMC)
Mesci et al,49 2012 –2.00 (–3.94 to –0.06)
Subtotal
Heterogeneity: τ2 = 0.00, χ 2 = 0.04 (P =.84), I 2 = 0%
Test for overall effect: Z = 2.56 (P =.01)
–2.0 0.99 17.3
Mesci et al,49 2012
Total
Heterogeneity: τ2 = 0.00, χ  2 = 8.72 (P =.56), I 2 = 0%
Test for overall effect: Z = 4.64 (P <.001)
Test for subgroup differences: χ 2 = 3.14 (P =.21), I 2 = 36.4%2
DS indicates deep sclerectomy; IV, inverse-variancemethod; MMC, mitomycin C; and TE, trabeculectomy.
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out an implant and 6 studies32,38,44-46,49 of DS with an im-
plant. There was no between-group difference in the
comparisonofTEandDSwithoutan implant (MeD = −2.10mm
Hg [95%CI, −3.20 to −1.00]) or in the comparisonof TE andDS
with an implant (MeD = −1.79mmHg [95%CI, −3.13 to−0.45]).
The result of the test for subgroup difference was χ21 = 0.24
(P = .62).
Twostudies38,41wereexcluded fromtheanalysis of the 12-
month follow-updatabecauseofan insufficientdurationof fol-
low-up. Overall, TE led to a greater reduction in IOP than NPS
(Figure 4). There was a difference between the subgroups de-
fined by type of surgery (χ22 = 8.96; P = .01): the MeD de-
creased in favor of TE in the VCO group (from −2.84 mm Hg
[95% CI, −4.40 to −1.27] at 6 months to −3.84mmHg [95% CI,
−5.34 to −2.34] at 12months) and theCP group (from−3.10mm
Hg [95% CI, −7.63 to 1.43] at 6 months to −4.40 mm Hg [95%
CI, −8.89 to 0.09] at 12months) but increased in favor of DS in
the DS group (from −1.91 mm Hg [95% CI, −2.72 to −1.10] at 6
months to −1.53mmHg [95%CI, −2.59 to −0.47] at 12months).
Sensitivity Analysis
Two studies32,45 in which the first IOP evaluation was made
after 6 months were excluded from the 6-month sensitivity
analysis, and 1 study45 in which the first IOP evaluation was
made after 12 months was excluded from the 12-month sen-
sitivity analysis. A further 3 studies32,33,44were excluded from
the analyses of only randomized clinical trials. The results of
these sensitivity analyses were always consistent with those
of the primary analysis.
Safety Evaluation
The results of the analysis of postoperative complications are
shown inTable 3. Theabsolute riskofhypotony (RR = 2.3 [95%
CI, 1.3-3.8]), choroidaleffusion (RR = 3.9 [95%CI,2.0-7.5]), cata-
Figure 4. Trabeculectomy vs Nonpenetrating Surgery at 12-Month Follow-up
–15 0 10 15–5 5
Favors TE Favors NPS
–10
Source
TE vs VCO
Mean Difference, IV,
Random (95% CI)
Mean Difference, IV,
Random (95% CI)
Carassa et al,34 2003 –1.47 (–6.12 to 3.18)
Gilmour et al,40 2009 –4.56 (–7.89 to –1.23)
Kobayashi et al,42 2003 –4.30 (–6.53 to –2.07)
Lüke et al,43 2002 –1.80 (–6.09 to 2.49)
Yalvac et al,47 2004 –5.70 (–11.13 to –0.27)
Yarangümeli et al,48 2004 –3.90 (–11.43 to 3.63)
Subtotal  –3.84 (–5.34 to –2.34)
Heterogeneity: τ2 = 0.00, χ 2 = 2.66 (P =.75), I 2 = 0%
Test for overall effect: Z = 5.01 (P <.001)
5
TE vs CP
Ayyala et al,33 2011 –4.40 (–8.89 to 0.09)
Subtotal
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P =.05)
Mean
Difference
–1.47
–4.56
–4.30
–1.80
–5.70
–3.90
–4.40    
SE
2.37
1.70
1.14
2.19
2.77
3.84
2.29
Weight, %
3.4
5.6
9.1
3.9
2.6
1.5
26.1
16
3.6
–4.40 (–8.89 to 0.09)3.6
–2.22 (–3.18 to –1.27)100.0
Subtotal
Heterogeneity: τ2 = 0.99, χ  2 = 14.48 (P =.11), I 2 = 38%
Test for overall effect: Z = 2.83 (P =.005)
–1.53 (–2.59 to –0.47)70.2
–3.16 (–5.85 to –0.47)–3.16 1.37 7.4
TE vs DS
Ambresin et al,32 2002 –7.50 (–13.13 to –1.87)–7.50 2.87 2.5
Chiselita,35 2001
3.20 (–1.19 to 7.59)3.20 2.24 3.8
Cillino et al,36 2004 –2.70 (–4.82 to –0.58)–2.70 1.08 9.5
Cillino et al,37 2008
–0.40 (–2.11 to 1.31)–0.40 0.87 11.4
Mermoud et al,44 1999 –0.60 (–4.09 to 2.89)–0.60 1.78 5.3
Mesci et al,49 2012
–1.00 (–2.71 to 0.71)–1.00 0.87 11.4
Mesci et al,49 2012 –1.50 (–3.09 to 0.09)–1.50 0.81 12.0
Russo et al,45 2008
–6.60 (–17.73 to 4.53)–6.60 5.68 0.7
El Sayyad et al,39 2000 –1.80 (–4.88 to 1.28)–1.80 1.57 6.3
Schwenn et al,46 2004
Total
Heterogeneity: τ2 = 1.33, χ  2 = 26.10 (P =.05), I 2 = 39%
Test for overall effect: Z = 4.56 (P <.001)
Test for subgroup differences: χ 2 = 8.96 (P =.01), I 2 = 77.7%2
9
CP indicates canaloplasty; DS, deep sclerectomy; IV, inverse-variancemethod; NPS, nonpenetrating surgery; TE, trabeculectomy; and VCO, viscocanalostomy.
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ract (RR = 3.4 [95% CI, 2.1-5.5]), or a flat or shallow anterior
chamber (RR = 4.3 [95%CI, 2.3-8.0])washigher in theTEgroup
than in the NPS group.
In thecomparisonofTEandVCO, theRRs for all of thecon-
sidered complications increasedwhenMMCwas added to TE
(RR of hypotony increased from 2.3 to 11.0; RR of cataract in-
creased from 3.6 to 5.0; and RR of a flat or shallow anterior
chamber increased from 4.7 to 9.0).
In the comparison of TE and DS, the RRs of all of the con-
sidered complications except cataract (RR increased from3.0
to 3.9) decreased when MMC was added to both (RR of hy-
potony decreased from2.2 to 1.7; RR of choroidal effusion de-
creased from 6.1 to 2.4; and RR of a flat or shallow anterior
chamber decreased from 8.3 to 3.1).
Discussion
Toour knowledge, this is the firstmeta-analysis that assesses
efficacy and safety of TE vs all of the available NPS proce-
dures. The results of this systematic review suggest that TE is
more effective in reducing IOP than NPS 6 and 12 months af-
ter surgery (−2.15 mm Hg [95% CI, −2.85 to −1.44] and −2.22
[95%CI, −3.18 to−1.27], respectively). The significanceof such
differences in IOP is likely to be clinically relevant especially
inpatients requiring agreater IOP reductionor those at greater
risk for glaucoma progression. Among the NPS procedures,
there was less difference in efficacy between DS and TE, al-
though the superiority of TE was statistically significant.
These results are in line with what is generally believed
about so-called canal surgery (VCO and CP), which cannot be
expected to lower IOP as much as the bulk flow of the full-
thickness perforation created in the eye bymeans of TE.Deep
sclerectomy seems to be a clinically reasonable compromise
in terms of reducing IOP.
With regard to the efficacy of TE and DS with or without
MMC, the additionofMMC tobothdecreased thedifference in
the reduction in IOP: TE and DS without MMC, −2.65 mm Hg
(95% CI, −3.90 to −1.39); TE and DS with MMC, −0.83 mm Hg
(95% CI, −2.40 to 0.74). This indicates that the use of MMC is
advisable when performing DS because the nature of the pro-
cedure (filtering surgery: filtration of aqueous humor into the
subconjunctival spaces)means that antimetabolites can avoid
conjunctival healing and optimize surgical outcomes.
The implantation of drainage devices during DS has
been advocated as a means of increasing the success rate of
the procedure,50,51 but our meta-analysis shows no signifi-
cant difference in the reduction in IOP induced by DS with
or without drainage devices (test for subgroup differences:
χ21 = 0.24; P = .62). This finding has important implications
in clinical practice because the use of implants significantly
increases the cost of DS, which is otherwise the same as that
of standard TE.
As expected, TEwas associatedwith ahigher incidenceof
short- and long-term complications. Viscocanalostomy had a
better safety profile than TE, although the evidence concern-
ing CP was not sufficient to draw any conclusion.
It has been claimed that the additional use of intraop-
erative MMC increases surgery-related complications. Our
findings show that without MMC, TE led to a higher inci-
dence of complications than DS, but when both procedures
were supplemented with MMC, the rate of complications
(except cataract progression) increased in the DS group. One
possible explanation is that DS has not been modified from
the original technique (with or without the use of MMC),
whereas standard TE has been substantially improved since
the advent of antimetabolites. The term safe trabeculectomy
reflects a development that can be considered as optimizing
the technique and postoperative management (suture lysis,
bleb manipulation).52-54
In conclusion,TEstill offers thepossibilityofobtainingex-
cellent IOP control at the long-term follow-up inpatientswith
OAG.Successmayvarydependingonglaucomaform, ie, itmay
work better in XFG, whereas NPS procedures are not a viable
option in chronic angle-closure glaucoma.Moreover,NPSpro-
cedures aremore difficult to perform, require a long learning
curveevenforanexperiencedglaucomasurgeon,andaremore
costly. Despite a higher incidence of postoperative complica-
Table 3. Complications
Subgroup
Hypotony Choroidal Effusion Cataract
Flat or Shallow
Anterior Chamber
Studies, No.
(Eyes, No.)
RR
(95% CI)
Studies, No.
(Eyes, No.)
RR
(95% CI)
Studies, No.
(Eyes, No.)
RR
(95% CI)
Studies, No.
(Eyes, No.)
RR
(95% CI)
TE vs VCO 6 (303) 2.6 (1.2-5.6) 3 (159) 6.0 (1.1-33.8) 4 (204) 3.8 (1.5-9.5) 3 (154) 5.5 (1.2-25.1)
TE (no MMC) vs VCO 5 (253) 2.3 (1.1-5.0) 3 (159) 6.0 (1.1-33.8) 3 (154) 3.6 (1.4-9.7) 2 (104) 4.7 (0.7-32.6)
TE (+MMC) vs VCO 1 (50) 11.0 (0.6-188.9) NA NA 1 (50) 5.0 (0.3-99.2) 1 (50) 9.0 (0.5-158.9)
TE vs DS 7 (399) 2.1 (0.9-4.6) 7 (409) 3.8 (1.6-9.0) 6 (424) 3.3 (1.8-5.8) 9 (521) 4.1 (2.1-8.0)
TE (no MMC) vs DS
(no MMC)
3 (153) 2.2 (0.5-8.8) 3 (163) 6.1 (1.9-19.9) 4 (240) 3.0 (1.3-6.6) 5 (275) 8.3 (2.6-26.7)
TE (no MMC) vs DS
(+MMC)
1 (91) 3.1 (1.6-6.3) 1 (91) 15.6 (0.9-281.3) 1 (91) 3.5 (1.3-9.4) 1 (91) 2.8 (1.0-7.9)
TE (+MMC) vs DS
(+MMC)
3 (155) 1.7 (0.4-6.3) 3 (155) 2.4 (0.6-9.8) 1 (93) 3.9 (0.9-17.0) 3 (155) 3.1 (0.6-16.7)
TE vs CP NA NA 1 (79) 12.3 (0.7-205.9) NA NA NA NA
TE vs NPS 13 (702) 2.3 (1.3-3.8) 11 (647) 3.9 (2.0-7.5) 10 (628) 3.4 (2.1-5.5) 12 (675) 4.3 (2.3-8.0)
Abbreviations: CP, canaloplasty; DS, deep sclerectomy; MMC, mitomycin C; NA, not applicable; NPS, nonpenetrating surgery; RR, relative risk; TE, trabeculectomy;
VCO, viscocanalostomy.
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tions when compared with NPS, the advent of the safe tra-
beculectomy technique offers the possibility of tailoring the
IOP postoperatively with minimal postoperative complica-
tions. Therefore, further studies are needed to assess the
safety profile of the current TE procedure compared with
NPS techniques.
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OPHTHALMIC IMAGES
Entopic Image of Dislocated Intraocular Lens
Jennifer Tordilla-Wadia, MD; Sejal Shah, MD; Curtis E. Margo, MD, MPH
A B
C
A 67-year-old man, with history of right cataract extraction surgery 10 years earlier then retinal detachment with
therapeutic vitrectomy 1 year later, experienced severe blurred vision in the eye for 1 week. Visual blur was interrupted
with the transient image of a “gasket,” which he could draw better than explain verbally (A). Visual acuity was 20/25 with
+8-diopter correction. On reclined fundus examination, a plate haptic intraocular lens (IOL) was observed floating in front
of themacula (B). The dislocated IOL was removed surgically (C) and replaced with an anterior chamber IOL. The cloudy
edge of the entopic image corresponded to adherent lens capsule to the IOL (C, insert; periodic acid–Schiff; bar = 20 μm).
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